Lucid Diagnostics Inc.
Business
Lucid Diagnostics is a commercial-stage cancer-prevention diagnostics company offering EsoGuard, a DNA methylation test for early detection of esophageal adenocarcinoma in at-risk GERD patients. The test uses cells collected via the FDA-cleared EsoCheck swallowable device and is performed in Lucid's CLIA-certified laboratory. The company commercializes through Lucid Test Centers, satellite programs, employer contracts, and telemedicine partnerships, with reimbursement from Medicare, commercial insurers, and Veterans Affairs.
Summary from 10-K filed 2026-03-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 5 | 4 | — | — | — | |
| Cost of revenue | 7 | 7 | — | — | 585,000 | |
| Sales and marketing | 18 | 16 | 16 | 16 | 5 | |
| General and administrative | 24 | 20 | 19 | 24 | 13 | |
| Amortization of acquired intangible assets | 421,000 | 688,000 | 2 | 2 | 0 | |
| Research and development | 6 | 6 | 7 | 11 | 9 | |
| Total operating expenses | 54 | 50 | — | — | — | |
| Operating loss | −50 | −46 | −48 | −56 | −27 | |
| Interest income | 386,000 | 322,000 | — | — | — | |
| Interest expense | −22,000 | −26,000 | — | — | — | |
| Change in fair value - Senior Secured Convertible Note | −8 | 5 | — | — | — | |
| Debt extinguishments loss - Senior Secured Convertible Note | 0 | −5 | −26,000 | — | — | |
| Equity issuance cost extinguishment | −1 | 0 | — | — | — | |
| Other income (expense), net | −8 | 523,000 | — | — | — | |
| Loss before provision for income tax | −58 | −46 | −53 | −56 | −28 | |
| Provision for income taxes | 0 | 0 | — | — | — | |
| Net loss attributable to Lucid Diagnostics Inc. | −58 | −46 | −53 | −56 | −28 | |
| Net loss attributable to Lucid Diagnostics Inc. common stockholders | −71 | −53 | −53 | — | — | |
| Net loss per share attributable to Lucid Diagnostics Inc. common stockholders - basic and diluted (in dollars per share) | −0.69 | −1.05 | −1.26 | −1.55 | −1.51 | |
| Weighted average common shares outstanding, basic and diluted (in shares) | 102 | 51 | 42 | 36 | 19 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 35 | 22 | — | — | 54 | |
| Accounts receivable | 643,000 | 45,000 | 45,000 | 17,000 | 200,000 | |
| Inventory | 353,000 | 341,000 | 278,000 | 111,000 | — | |
| Prepaid expenses, deposits, and other current assets | 2 | 2 | 3 | 2 | 3 | |
| Total current assets | 37 | 25 | 22 | 24 | 57 | |
| Fixed assets, net | 809,000 | 1 | 1 | 2 | 971,000 | |
| Operating lease right-of-use assets | 2 | 3 | 1 | 2 | — | |
| Intangible assets, net | 315,000 | 736,000 | 1 | 3 | — | |
| Other assets | 47,000 | 1 | 1 | 1 | 725,000 | |
| Total assets | 40 | 31 | 27 | 33 | 59 | |
| Accounts payable | 970,000 | 1 | 1 | 1 | 1 | |
| Accrued expenses and other current liabilities | 3 | 3 | — | — | — | |
| Operating lease liabilities, current portion | 893,000 | 854,000 | 1 | 962,000 | — | |
| Senior Secured Convertible Notes - at fair value | 24 | 19 | 14 | — | — | |
| Total current liabilities | 29 | 24 | 29 | 8 | 4 | |
| Operating lease liabilities, less current portion | 927,000 | 2 | 199,000 | 1 | — | |
| Total liabilities | 30 | 25 | 30 | 9 | 4 | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Preferred stock, $0.001 par value, 20,000,000 shares authorized; Series B and Series B-1 Convertible Preferred Stock, issued and outstanding 54,274 and 54,419 as of December 31, 2025 and December 31, 2024, respectively | 54 | 54 | 19 | — | — | |
| Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 131,098,762 and 63,071,950 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 131,000 | 63,000 | 42,000 | 41,000 | 35,000 | |
| Additional paid-in capital | 231 | 155 | 130 | 121 | 97 | |
| Accumulated deficit | −274 | −204 | −151 | −98 | −42 | |
| Total Stockholders Equity (Deficit) | 11 | 5 | −2 | 23 | 55 | |
| Total Liabilities and Stockholders Equity (Deficit) | 40 | 31 | 27 | 33 | 59 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization expense | 872,000 | 1 | 2 | 2 | 4,000 | |
| Amortization of common stock payment for vendor service agreement | 234,000 | 346,000 | — | — | — | |
| Accounts receivable | −601,000 | 0 | −28,000 | 183,000 | −200,000 | |
| Prepaid expenses and other current assets | −2 | 1 | — | — | −2 | |
| Accounts payable | −270,000 | 96,000 | 89,000 | −445,000 | −665,000 | |
| Accrued expenses and other current liabilities | −110,000 | −1 | 2 | 333,000 | 926,000 | |
| Net cash flows used in operating activities | −47 | −44 | −33 | −30 | −18 | |
| Purchase of equipment | −197,000 | −296,000 | — | −3 | — | |
| Net cash flows used in investing activities | −197,000 | −646,000 | −221,000 | −4 | −862,000 | |
| Proceeds issue of preferred stock | 0 | 30 | 19 | — | — | |
| Proceeds issue of Senior Secured Convertible Notes | 360,000 | 22 | 10 | — | — | |
| Payment repayment of Senior Secured Convertible Note | 0 | −4 | — | — | — | |
| Proceeds exercise of stock options | 17,000 | 4,000 | — | 695,000 | — | |
| Proceeds issue common stock Employee Stock Purchase Plan | 272,000 | 447,000 | — | — | — | |
| Net cash flows provided by financing activities | 59 | 48 | 29 | 3 | 72 | |
| Net increase (decrease) in cash | 12 | 3 | −4 | −31 | 54 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Lucid Diagnostics Inc.'s CIK number?
Lucid Diagnostics Inc.'s SEC CIK number is 0001799011 (1799011). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Lucid Diagnostics Inc.'s SEC filings?
All of Lucid Diagnostics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Lucid Diagnostics Inc. last report earnings?
Lucid Diagnostics Inc. (LUCD) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-022877). This is Lucid Diagnostics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Lucid Diagnostics Inc.'s most recent earnings 8-K?
Lucid Diagnostics Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001493152-26-022877. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Lucid Diagnostics Inc.'s latest earnings 8-K →
Look up any company's CIK number →